Company intelligence
Alumis
Transforming the lives of patients living with immune-mediated diseases using a precision approach.
About Alumis
Alumis is a late-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases designed to improve health outcomes – empowering people to reimagine their lives. What sets us apart is our precision approach to R&D. Our proprietary data analytics platform integrates genetic, genomic, proteomic, biological, and clinical insights to pinpoint the right targets, molecules, indications, patients, endpoints, and combinations – potentially accelerating development, enhancing therapy precision, and improving the probability of clinical success. Combined with our integrated approach to drug development, we believe this will drive smarter, faster progress against immune dysfunction.
Verified activity
Signals from Alumis
2 published signals
Presence & Recognition
Alumis will have members of the executive committee on the road in September for investor meetings and conference participation in Boston and New York.
Reported by Alumis
Presence & Recognition
Alumis amplified the National Psoriasis Foundation's reminder that psoriasis isn’t contagious but awareness is.
Reported by Alumis